Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 8/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11533303 | 0.98 | CXCR4 (0.71) | CXCR4ALDH1A1ATMSIGMAR1CYP2A13 | |
| SCHEMBL5824541 | 0.90 | CXCR4 (0.65) | CXCR4ALDH1A1ATMSIGMAR1CYP2A13 | |
| SCHEMBL31669240 | 0.90 | CXCR4 (0.65) | CXCR4ALDH1A1ATMSIGMAR1CYP2A13 | |
| Hydrochloric Acid SCHEMBL28987734 | 0.89 | CXCR4 (0.63) | CXCR4ALDH1A1ATMSIGMAR1CYP2A13 | |
| SCHEMBL11386928 | 0.87 | CXCR4 (0.57) | CXCR4ALDH1A1ATMSIGMAR1CYP2A13 | |
| SCHEMBL29767427 | 0.85 | CXCR4 (1.00) | CXCR4ALDH1A1ATMSIGMAR1CYP2A13 | |
| SCHEMBL11360607 | 0.83 | SIGMAR1 (0.85) | CXCR4ALDH1A1ATMSIGMAR1CYP2A13 | |
| SCHEMBL8551996 | 0.83 | CXCR4 (0.69) | CXCR4ALDH1A1ATMSIGMAR1CYP2A13 | |
| SCHEMBL12013926 | 0.83 | CXCR4 (0.69) | CXCR4ALDH1A1ATMSIGMAR1CYP2A13 | |
| SCHEMBL30443238 | 0.81 | CXCR4 (0.77) | CXCR4ALDH1A1ATMSIGMAR1CYP2A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-04-17 | — | — | US | disclosed |
| US-11963954-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114685519-B | Pyranocarbazole alkaloid derivatives and application thereof in treating Alzheimer's disease | 中国医学科学院药物研究所 | 2023-09-26 | — | — | CN | disclosed |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| CN-114685519-A | Pyrano-carbazole alkaloid derivative and application thereof in treating Alzheimer's disease | 中国医学科学院药物研究所 | 2022-07-01 | — | — | CN | disclosed |
| EP-3349743-B1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | ST JUDE CHILDRENS RES HOSPITAL (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-03-11 | — | — | US | disclosed |
| US-20180256558-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-09-13 | — | — | US | disclosed |
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0111397-B1 | ISOINDOLE DERIVATIVES, PREPARATION, AND USES | Bristol-Myers Company (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4600758-A | 5-SULFAMOYL-3-OXOISOINDOLES WITH ARLYPIPERIDINYL MOIETIES, DIURETICS, HYPOTENSIVES | MEAD JOHNSON & COMPANY (US) | 1986-07-15 | — | — | US | disclosed |
| US-4495194-A | HYPOTENSIVE AGENTS; DIURETICS | MEAD JOHNSON & COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0111397-A1 | Isoindole derivatives, preparation, and uses | Bristol-Myers Company (US) | 1984-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | CXCR4 1646/4885ALDH1A1 2147/4885ATM 2098/4885 |
| US-20180256558-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | CXCR4 4465/4885ALDH1A1 1996/4885ATM 3318/4885 |
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | CUL3, CUL1, CUL5 | CXCR4 3890/4885ALDH1A1 1133/4885ATM 3142/4885 |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | CXCR4 4465/4885ALDH1A1 1996/4885ATM 3318/4885 |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | CXCR4 4465/4885ALDH1A1 1996/4885ATM 3318/4885 |
| US-11963954-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | CXCR4 4465/4885ALDH1A1 1996/4885ATM 3318/4885 |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | CXCR4 4465/4885ALDH1A1 1996/4885ATM 3318/4885 |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | CXCR4 4465/4885ALDH1A1 1996/4885ATM 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.